HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?

被引：21

作者：

Freeman, MR ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Childrens Hosp Boston, Urol Dis Res Ctr,Enders Res Labs, Boston, MA 02115 USA

来源：

CANCER CELL | 2004年 / 6卷 / 05期

关键词：

D O I：

10.1016/j.ccr.2004.10.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this issue of Cancer Cell, Mellinghoff et al. (2004) demonstrate that a small molecule inhibitor of the EGF receptor (EGFR) and the HER2/ErbB2/c-Neu kinase blocks signaling to the androgen receptor by a mechanism that involves HER2/HER3 heterodimerization. Surprisingly, the EGFR is peripheral to this signaling mechanism. These results have implications for the design of targeted therapy for hormone-refractory prostate cancer.

引用

页码：427 / 428

页数：2

共 50 条

[11] Novel agents that downregulate EGFR, HER2, and HER3 in parallel
Ferreira, Renan Barroso
Law, Mary Elizabeth
Jahn, Stephan Christopher
Davis, Bradley John
Heldermon, Coy Don
Reinhard, Mary
Castellano, Ronald Keith
Law, Brian Keith
ONCOTARGET, 2015, 6 (12) : 10445 - 10459
[12] Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2
Zhang, K
Sun, JL
Liu, NL
Wen, DZ
Chang, D
Thomason, A
Yoshinaga, SK
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (07) : 3884 - 3890
[13] HER1, HER2, HER3 and HER4 gene copy number and protein expression in non-small cell lung cancer
Jeon, Y.
Kim, Y.
Sung, S.
Seo, J.
Chung, D.
HISTOPATHOLOGY, 2008, 53 : 350 - 350
[14] The involvement of EGFR, HER2 and HER3 in the basal cell carcinomas aggressiveness
Florescu, Diana Elena
Stepan, Alex Emilian
Margaritescu, Claudiu
Ciurea, Raluca Niculina
Stepan, Mioara-Desdemona
Simionescu, Cristiana Eugenia
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2018, 59 (02): : 479 - 484
[15] Effects of HER2 and HER3 on EGFR trafficking and localization - a modelling study
Resat, H
Shankaran, H
Wiley, H
MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 13A - 13A
[16] Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer
Krähn, G
Leiter, U
Kaskel, P
Udart, M
Utikal, J
Bezold, G
Peter, RU
EUROPEAN JOURNAL OF CANCER, 2001, 37 (02) : 251 - 259
[17] The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors
Cirstea, Andreea-Elena
Stepan, Alex Emilian
Margaritescu, Claudiu
Zavoi, Roxana Eugenia
Olimid, Daniel Alin
Simionescu, Cristiana Eugenia
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (04): : 1269 - 1273
[18] TRANSMODULATION OF HER2 LEVELS BY HER1 ACTIVATION
WORTHYLAKE, B
WILEY, HS
MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 1374 - 1374
[19] Transactivation of HER2 by phosphorylated HER3 and EGFR correlates with clinicopathological end points in HER2 negative NSCLC
Mohan, Kamlesh
Dodson, Andrew
Gosney, John
Carr, Martin
Thomas, Andrew
Womack, Chris
Jenkins, Martin
McGuire, Joe
Walshaw, Martin
Armour, Alison
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S897 - S898
[20] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
Hanker, Ariella B.
Jayanthan, Harikrishna Sekar
Ye, Dan
Lin, Chang-Ching
Akamatsu, Hiroaki
Sheehan, Jonathan H.
Koch, James P.
Sudhan, Dhivya R.
Brewer, Monica Red
Servetto, Alberto
He, Jie
Miller, Vincent A.
Lalani, Alshad S.
Meiler, Jens
Arteaga, Carlos L.
CANCER RESEARCH, 2020, 80 (04)

← 1 2 3 4 5 →